Growth, Trends, and Opportunities in the Shingrix (Zostavax) Market: Key Insights for the Next Decade
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Long-Term Projected Growth Rate for the Shingrix (Zostavax) Market, and What Are the Key Drivers?
In recent times, the market size of Shingrix (Zostavax) has demonstrated a robust HCAGR of XX%. The value of this sector is predicted to increase from $XX million in 2024 to $XX million in 2025, scaling at a Compound Annual Growth Rate (CAGR) of XX%. The market expansion throughout the historical period has been driven by greater acceptance of vaccines, growing emphasis on educational campaigns and preventative healthcare, along with amplified patient awareness and advocacy initiatives. Also, heightened insurance coverage for immunization has also contributed to this growth.
It is forecasted that the market size of shingrix (zostavax) would witness XX (FCAGR) growth in the upcoming years. This market expansion is anticipated to reach an estimated $XX million in 2029, associated with a compound annual growth rate (CAGR) of XX%. This prediction for growth during the forecast period is influenced by contributing factors such as a growing elderly population, an escalated frequency of herpes zoster, increased chickenpox incidence, a rise in disease prevalence, and heightened understanding about shingles and its ensuing complications. Noteworthy trends for this forecast period encompass innovative recombinant vaccinations, advancements in the process of vaccine creation, a pivot towards disease prevention rather than treatment, AI-assisted research and development in vaccination, and novel biomarker identification for susceptibility to shingles.
What Are the Primary Drivers Supporting the Growth of the Shingrix (Zostavax) Market?
The escalation in the number of people getting vaccinated is forecasted to enhance the growth of the shingrix (zostavax) market in the future. Vaccination involves introducing a vaccine into the body to provoke the immune system to identify and combat specific disease-causing organisms. This increasing trend towards vaccination is linked to heightened public understanding of its role in disease prevention, decreasing the impact of diseases, and the creation of secure and readily available vaccines. Enhanced healthcare facilities, public health drives, and international initiatives promoting vaccination also play a part in its acceptance across the globe. Shingrix (Zostavax) plays an advantageous role in vaccination by providing potent protection from shingles and associated problems. It shows significant benefits for adults aged over 50, substantially decreasing the likelihood of shingles relapse and post-herpetic neuralgia. For example, a study published by the Journal of the American Medical Association (JAMA), a US-based medical journal in May 2024, indicated a 46% increase in shingles vaccinations covered by Medicare Part D the year following the implementation of the IRA policy in January 2023. Furthermore, in 2022, as per the Australian Government Department of Health and Aged Care, the Australian government assured that COVID-19 vaccines were made readily available to every Australian. As of mid-2022, over 34 million primary vaccinations and booster shots were dispensed, with major participation from general practices, notably in rural regions. Consequently, the surge in vaccine adoption is fuelling the growth of the shingrix (zostavax) market.
Explore Comprehensive Insights Into The Global Shingrix (Zostavax) Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20264&type=smp
Which Companies Are Leading the Charge in Expanding the Shingrix (Zostavax) Market?
Major companies operating in the shingrix (zostavax) market are GSK plc
What New Trends Are Reshaping the Shingrix (Zostavax) Market and Its Opportunities?
One primary progression in the shingrix (zostavax) market is the innovation of new products. These focus on augmenting the effectiveness of vaccines and tackling the decreasing immunity in susceptible groups as they age through the creation of non-live, recombinant subunit adjuvanted vaccines. This type of vaccine uses specific protein components from a pathogen, supplemented with an adjuvant to amplify the immune response. An example of this is the September 2024 launch of the Shingrix shingles vaccine by UK-based biopharmaceutical firm, GSK plc. The Recombinant Zoster Vaccine (RZV) is a non-live vaccine that offers as much as 97% efficiency in protecting against shingles and post-herpetic neuralgia. Aiming at adults who are 50 years old or over and those who are immunocompromised and aged 18 or over, the vaccine is administered in two injections into the muscle tissue. The ZOE-50 study demonstrated that RZV’s an efficacy rate of up to 97% in adults aged 50 and older over a three-year period, with recent evidence suggesting the maintained efficiency at over 80% for 6–10 years following vaccination.
Secure Your Global Shingrix (Zostavax) Market Report Now for Fast and Efficient Delivery!
https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report
What Major Market Segments Define the Scope and Growth of the Shingrix (Zostavax) Market?
The shingrix (zostavax) market covered in this report is segmented –
1) By Formulation: Recombinant Vaccine (Shingrix); Live Attenuated Vaccine (Zostavax)
2) By Indication: Shingles Prevention; Post-Herpetic Neuralgia
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy
What Are the Top Regions Fueling Growth in the Shingrix (Zostavax) Market?
North America was the largest region in the shingrix (zostavax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Is the Shingrix (Zostavax) Market Defined Across Different Regions?
Shingrix (Zostavax) refers to a vaccine designed to prevent shingles (herpes zoster), a painful rash caused by the reactivation of the varicella-zoster virus. It is used for immunizing adults, particularly those aged 50 and older, to reduce the risk of developing shingles and its complications.
Browse Through More Similar Reports By The Business Research Company:
Human Immunodeficiency Virus (HIV) Diagnosis Global Market Report 2025
Immunoglobulin E (IgE) Allergy Blood Tests Global Market Report 2025
Immunomodulator Global Market Report 2025
https://thebusinessresearchcompany.com/report/immunomodulator-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: